Acute coronary syndromes articles from across Nature Portfolio

Heart failure is the most prevalent complication of acute myocardial infarction. Here, the authors show that circulating S100A8/A9 is a robust predictor and potentially causal medicator for heart failure post-acute myocardial infarction, as such could serve as a promising drug target for cardioprotection.

Non-coding RNAs are implicated in the pathophysiology of ischaemic heart disease and heart failure. In this Review, Caporali and colleagues examine the biology of these molecules and discuss the potential of non-coding RNAs for translation to the clinic as biomarkers and therapeutics in adverse cardiac remodelling leading to ischaemic heart failure.

After myocardial infarction, the heart secretes small extracellular vesicles with pro-neoplastic properties that can accelerate tumour growth when taken up by cancer cells.

In ST-segment elevation myocardial infarction, the role of interventional modification of thrombi in the coronary arteries before stenting is controversial. However, innovations in stroke intervention have sparked renewed interest in thrombus modification approaches. We discuss current and emerging techniques to extract or disperse thrombi, aiming to reduce downstream embolization, microvascular obstruction and myocardial injury.

In coronary artery disease, the transition from an apparently stable state to a life-threatening acute cardiac event is difficult to predict. As such, a recent study applied proteomic and metabolomic approaches to discover new biomarkers that signal imminent myocardial infarction.

Pro-reparative cardiac-resident macrophages have emerged as major players in salvaging the ischemic myocardium of a diseased heart. New research now highlights ATF3 as a key transcription factor that governs macrophage survival and proliferation and myocardial repair.

During myocardial infarction, haematopoietic stem and progenitor cells increase fatty acid oxidation, and bone marrow adipocytes can act as a local energy resource for these cells.

A liberal strategy of blood transfusion might improve outcomes in patients with acute myocardial infarction and anaemia, according to results from the MINT trial.